673 A |
| Catalog No.GC50613 |
ALDH1A inhibitor; depletes CD133+ cancer stem cells (CSC)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 109437-62-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Aldehyde dehydrogenase (ALDH1A) inhibitor (IC50 values are 230, 246 and 348 nM for ALDH1A2, ALDH1A1 and ALDH1A3, respectively). Exhibits >40-fold selectivity for ALD1A over ALDH2. Depletes CD133+ cancer stem cells (CSC) in ovarian cancer cell lines. Triggers necroptosis in ovarian CSCs and induces expression of mitochondrial uncoupling proteins (UCP). Overcomes chemotherapy resistance in vivo.
Chefetz et al (2019) A pan-ALDH1A inhibitor induces necroptosis in ovarian cancer stem-like cells. Cell Rep. 26 3061 PMID:30865894 |Raghavan et al (2017) Personalized medicine-based approach to model patterns of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids. Clin.Cancer Res. 23 6934 PMID:28814433
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *